← All trials
NCT03824912
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2018
- Primary completion
- Jan 24, 2019
- Completion date
- Jan 24, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 831
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Encube Ethicals Pvt. Ltd.Lead sponsor
- Novum Pharmaceutical Research ServicesCollaborator
- Encube Ethicals Pvt. Ltd.Study director
- ACM Global LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.